Header Forschung

Institute of Radiopharmaceutical Cancer Research

The Institute of Radiopharmarmaceutical Cancer Research is headed by Prof. Dr. Klaus Kopka and Prof. Michael Bachmann. Prof. Kopka is W3-professor of "Bioinorganic and Radiopharmaceutical Chemistry" at Technische Universität Dresden. Prof. Bachmann is W3-professor of "Translational Radiopharmacology in Oncology" at Technische Universität Dresden.

Essentially the scientific work of the institution aims at the development of radiolabeled substances for diagnostic and therapeutic purposes. These are primarily substances for Positron Emission Tomography (PET) capable for functional diagnoses of cancer (and other  diseases),follow-up investigations after therapeutic interventions and for individual tumor characterization. Therapeutic substances based on peptides and antibodies are radiolabeled with particle-emitting radionuclides for targeted destruction of tumor tissue.

This general aim requires a broad scale of scientific work starting with the production of radionuclides, chemical syntheses, developing of labeling procedures and the determination of the radiopharmacological properties of the radiolabeled substances in vitro and in vivo. Accordingly, specialists from various disciplines are required to meet all the demands for this kind of research.

The PET Center Dresden-Rossendorf is run within the scope of NCT Dresden. This institute is producing a variety of radiopharmaceuticals for human use on a regular basis applied by nuclear medicine specialists. Additionally, research results on radiolabeled substances are used for preclinical investigations (“molecular imaging”) of basic biochemical processes in vivo.

A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform
Albert, S.; Arndt, C.; Feldmann, A.; Bergmann, R.; Bachmann, D.; Koristka, S.; Ludwig, F.; Ziller-Walter, P.; Kegler, A.; Gärtner, S.; Schmitz, M.; Ehninger, A.; Cartellieri, M.; Ehninger, G.; Pietzsch, H.-J.; Pietzsch, J.; Steinbach, J.; Bachmann, M. OncoImmunology (2017)
Online First (2017) DOI-Link: http://dx.doi.org/10.1080/2162402X.2017.1287246

A novel tumor pretargeting system based on complementary L-configured oligonucleotides
Schubert, M.; Bergmann, R.; Förster, C.; Sihver, W.; Vonhoff, S.; Klussmann, S.; Bethge, L.; Walther, M.; Schlesinger, J.; Pietzsch, J.; Steinbach, J.; Pietzsch, H.-J. Bioconjugate Chemistry (2017)

Gelatin-based hydrogel degradation and tissue interaction in vivo: insights from multimodal preclinical imaging in immunocompetent nude mice
C. Tondera, S. Ullm, A. Krüger-Genge, F. Jung, A. T. Neffe, A. Lendlein, R. Klopfleisch, Steinbach, J. C. Neuber, J. Pietzsch, Theranostics 6(2016)12, 2114-2128 http://dx.doi.org/10.7150/thno.16614

Evaluation of the enantiomer specific biokinetics and radiation doses of [18-F]-fluspidine – a new tracer in clinical translation for imaging of σ1 receptors
Kranz, M.; Sattler, B.; Wüst, N.; Deuther-Conrad, W.; Patt, M.; Meyer, P. M.; Fischer, S.; Donat, C. K.; Wünsch, B.; Hesse, S.; Steinbach, J.; Brust, P.; Sabri, O. Molecules 21(2016), 1164
DOI-Link: http://dx.doi.org/10.3390/molecules21091164

Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure
Zschaeck, S.; Haase, R.; Abolmaali, N.; Perrin, R.; Stützer, K.; Appold, S.; Steinbach, J.; Kotzerke, J.; Zips, D.; Richter, C.; Gudziol, V.; Krause, M.; Zöphel, K.; Baumann, M. Acta Oncologica 54(2015), 1355-1363
DOI-Link: http://dx.doi.org/10.3109/0284186X.2015.1074720